Experiences with
Belimumab106 public posts
Want to take advantage of all our features? Just log in!
or
An indicator in the blood could guide lupus treatment
A clinical trial (called “BEAT-Lupus”) has found that using a combination of two biologic treatments, rituximab and belimumab, may be more effective than using rituximab alone in patients who have not responded well to other treatment.
SLE patients may have reduced response to COVID-19 vaccination
The use of the immunosuppressant medications CellCept (mycophenolate mofetil), tacrolimus and Benlysta (belimumab) significantly reduced IgG levels after vaccination.
Lupkinis plus MMF most effective in lupus nephritis; tacrolimus safest
Patients receiving IV cyclophosphamide were 75% less likely to achieve a complete response than those treated with tacrolimus, and 92% less likely than those treated with Benlysta (belimumab) plus MMF. Benlysta is an antibody designed to reduce the production of disease-causing autoantibodies.
Paul Howard to step down as LUPUS UK Chief Executive
There are several developments during my time as Chief Executive of LUPUS UK that I am proud to have overseen:
• NICE recommendations for the first two medicines (belimumab and voclosporin) to be licensed specifically for the treatment of lupus.
Greater use of Benlysta, Saphnelo seen in US, EU to treat lupus
To that end, healthcare professionals are increasingly prescribing biological therapies like Benlysta (belimumab) and Saphnelo (anifrolumab).
Those are the main findings of two new reports from Spherix Global Insights, a U.S. company that tracks the global pharmaceutics market.
SMC approve belimumab (Benlysta) for use by NHS Scotland
Belimumab is taken in addition to other treatment for lupus and is either administered as an intravenous infusion, or sub-cutaneous injection (which can be self-administered).
[u]Who can have (Benlysta)?[/u]
You will not be offered if:
- your lupus isn’t active.
Treatments for Lupus May Reduce Response to COVID-19 Vaccination
Patients on rituximab had an 89% decrease in antibody levels compared with healthy controls, whereas those using belimumab had a 7% decrease.
B-cell protein sBCMA may be useful biomarker of SLE activity in children
Future studies to investigate the effects of more recently approved SLE therapies, such as Benlysta (belimumab), are also warranted, the researchers wrote.
https://lupusnewstoday.com/news/b-cell-protein-sbcma-useful-biomarker-activity-children/?